Top

Published in:

01-07-2020 | Liver Cirrhosis | Original Article

Association between MICA rs2596542 Polymorphism with the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients

Authors: Camila Guerra Marangon, Jóice Teixeira de Bitencorte, Rafael Tomoya Michita, Vagner Ricardo Lunge, Deivid Cruz dos Santos, Mário Reis Álvares-da-Silva, Daniel Simon

Published in: Pathology & Oncology Research | Issue 3/2020

Abstract

In this study we investigated the impact of rs2596542A/G single nucleotide polymorphism (SNP) in the major histocompatibility complex class I chain-related sequence A (MICA) gene on HCV-induced hepatocellular carcinoma (HCC) susceptibility in a Brazilian population. In total, 252 HCV-infected patients (98 with HCV-induced HCC and 154 non-malignant HCV-induced liver cirrhosis) were enrolled and 98 healthy control subjects (negative anti-HCV). The MICA rs2596542 SNP genotypes were determined by real-time PCR assay. No differences in MICA genotype frequencies between HCV-induced cirrhosis patients and controls were observed. However, genotype frequencies of rs2596542A/G SNP were statistically different between HCV-induced HCC patients and controls (p = 0.048), and also between HCC and HCV-induced cirrhosis patients (p = 0.039). The highest frequency of the rs2596542AA genotype was observed in HCC patients (31.6%) when compared with HCV-induced cirrhosis patients (18.8%) and healthy controls (19.4%). Also, rs2596542AA genotype carriers have an increased risk for HCC when compared to HCV-induced cirrhosis status [odds ratio (OR) = 1.99; 95% confidence interval (CI) = 1.06–3.74, p = 0.020)] and healthy individuals (OR = 1.92, 95% CI = 1.00–3.70, p = 0.049). Taken together our study suggest that MICA rs2596542 SNP impacts HCV-induced HCC susceptibility suggesting that genetic variants in MICA are of clinical relevance to hepatocarcinogenesis by impacting host immune response in chronic HCV infection.

Available only for authorised users

Tang H, Grisé H (2009) Cellular and molecular biology of HCV infection and hepatitis. Clin Sci (Lond) 117:49–65. https://doi.org/10.1042/CS20080631 CrossRef

El Khoury AC, Wallace C, Klimack WK, Razavi H (2012) Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. J Med Econ 15:887–896. https://doi.org/10.3111/13696998.2012.681332 CrossRefPubMed

Wong RJ, Gish RG (2016) Metabolic manifestations and complications associated with chronic hepatitis C virus infection. Gastroenterol Hepatol (N Y) 12:293–299 http://www.ncbi.nlm.nih.gov/pubmed/27499712

Lingala S, Ghany MG (2015) Natural history of hepatitis C. Gastroenterol Clin N Am 44:717–734. https://doi.org/10.1016/j.gtc.2015.07.003 CrossRef

Sebastiani G, Gkouvatsos K, Pantopoulos K (2014) Chronic hepatitis C and liver fibrosis. World J Gastroenterol 20:11033–11053. https://doi.org/10.3748/wjg.v20.i32.11033 CrossRefPubMedPubMedCentral

Balogh J, Victor D, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM, Monsour HP (2016) Hepatocellular carcinoma: a review. J Hepatocell Carcinoma 3:41–53. https://doi.org/10.2147/JHC.S61146 CrossRefPubMedPubMedCentral

Miki D, Ochi H, Hayes CN, Abe H, Yoshima T, Aikata H, Ikeda K, Kumada H, Toyota J, Morizono T, Tsunoda T, Kubo M, Nakamura Y, Kamatani N, Chayama K (2011) Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet 43:797–800. https://doi.org/10.1038/ng.876 CrossRefPubMed

Patin E, Kutalik Z, Guergnon J, Bibert S, Nalpas B, Jouanguy E, Munteanu M, Bousquet L, Argiro L, Halfon P, Boland A, Müllhaupt B, Semela D, Dufour J-F, Heim MH, Moradpour D, Cerny A, Malinverni R, Hirsch H, Martinetti G, Suppiah V, Stewart G, Booth DR, George J, Casanova J-L, Bréchot C, Rice CM, Talal AH, Jacobson IM, Bourlière M, Theodorou I, Poynard T, Negro F, Pol S, Bochud P-Y, Abel L, I.H.C.G.C. Swiss Hepatitis C Cohort Study Group (2012) French ANRS HC EP 26 Genoscan Study Group, Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology 143:1244–1252.e12. https://doi.org/10.1053/j.gastro.2012.07.097 CrossRefPubMedPubMedCentral

Urabe Y, Ochi H, Kato N, Kumar V, Takahashi A, Muroyama R, Hosono N, Otsuka M, Tateishi R, Lo PHY, Tanikawa C, Omata M, Koike K, Miki D, Abe H, Kamatani N, Toyota J, Kumada H, Kubo M, Chayama K, Nakamura Y, Matsuda K (2013) A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region. J Hepatol 58:875–882. https://doi.org/10.1016/j.jhep.2012.12.024 CrossRefPubMed

10.

Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N, Otsuka M, Tateishi R, Omata M, Nakagawa H, Koike K, Kamatani N, Kubo M, Nakamura Y, Matsuda K (2011) Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet 43:455–458. https://doi.org/10.1038/ng.809 CrossRefPubMed

11.

Bahram S, Bresnahan M, Geraghty DE, Spies T (1994) A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci U S A 91:6259–6263. https://doi.org/10.1073/pnas.91.14.6259, http://www.ncbi.nlm.nih.gov/pubmed/8022771

12.

Bauer S (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA, science (80-. ), vol 285, pp 727–729. https://doi.org/10.1126/science.285.5428.727 CrossRef

13.

Ghadially H, Brown L, Lloyd C, Lewis L, Lewis A, Dillon J, Sainson R, Jovanovic J, Tigue NJ, Bannister D, Bamber L, Valge-Archer V, Wilkinson RW (2017) MHC class I chain-related protein a and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue. Br J Cancer 116:1208–1217. https://doi.org/10.1038/bjc.2017.79 CrossRefPubMedPubMedCentral

14.

Schrambach S, Ardizzone M, Leymarie V, Sibilia J, Bahram S (2007) In vivo expression pattern of MICA and MICB and its relevance to auto-immunity and cancer. PLoS One 2:e518. https://doi.org/10.1371/journal.pone.0000518 CrossRefPubMedPubMedCentral

15.

Chen D, Gyllensten U (2014) MICA polymorphism: biology and importance in cancer. Carcinogenesis. 35:2633–2642. https://doi.org/10.1093/carcin/bgu215 CrossRefPubMed

16.

Zhang J, Basher F, Wu JD (2015) NKG2D ligands in tumor immunity: two sides of a coin. Front Immunol 6:97. https://doi.org/10.3389/fimmu.2015.00097 CrossRefPubMedPubMedCentral

17.

Baranwal AK, Mehra NK (2017) Major histocompatibility complex class I chain-related a (MICA) molecules: relevance in solid organ transplantation. Front Immunol 8:182. https://doi.org/10.3389/fimmu.2017.00182 CrossRefPubMedPubMedCentral

18.

Kumar V, Yi Lo PH, Sawai H, Kato N, Takahashi A, Deng Z, Urabe Y, Mbarek H, Tokunaga K, Tanaka Y, Sugiyama M, Mizokami M, Muroyama R, Tateishi R, Omata M, Koike K, Tanikawa C, Kamatani N, Kubo M, Nakamura Y, Matsuda K (2012) Soluble MICA and a MICA variation as possible prognostic biomarkers for HBV-induced hepatocellular carcinoma. PLoS One 7:e44743. https://doi.org/10.1371/journal.pone.0044743 CrossRefPubMedPubMedCentral

19.

Wang L-P, Niu H, Xia Y-F, Han Y-L, Niu P, Wang H-Y, Zhou Q-L (2015) Prognostic significance of serum sMICA levels in non-small cell lung cancer. Eur Rev Med Pharmacol Sci 19:2226–2230 http://www.ncbi.nlm.nih.gov/pubmed/26166647 PubMed

20.

Zhao Y-K, Jia C-M, Yuan G-J, Liu W, Qiu Y, Zhu Q-G (2015) Expression and clinical value of the soluble major histocompatibility complex class I-related chain a molecule in the serum of patients with renal tumors. Genet Mol Res 14:7233–7240. https://doi.org/10.4238/2015.June.29.16 CrossRefPubMed

21.

Li H, Liu F, Zhu H, Zhou X, Lu J, Chang H, Hu J (2016) Interaction between polymorphisms of IFN-γ and MICA correlated with hepatocellular carcinoma. Med Sci Monit 22:549–553. https://doi.org/10.12659/MSM.895101 CrossRefPubMedPubMedCentral

22.

Motomura T, Ono Y, Shirabe K, Fukuhara T, Konishi H, Mano Y, Toshima T, Yoshiya S, Muto J, Ikegami T, Yoshizumi T, Maehara Y (2012) Neither MICA Nor DEPDC5 Genetic Polymorphisms Correlate with Hepatocellular Carcinoma Recurrence following Hepatectomy. HPB Surg 2012:185496. https://doi.org/10.1155/2012/185496 CrossRefPubMedPubMedCentral

23.

Lange CM, Bibert S, Dufour J-F, Cellerai C, Cerny A, Heim MH, Kaiser L, Malinverni R, Müllhaupt B, Negro F, Semela D, Moradpour D, Kutalik Z, Bochud P-Y (2013) Swiss hepatitis C cohort study group, comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma. J Hepatol 59:504–509. https://doi.org/10.1016/j.jhep.2013.04.032 CrossRefPubMed

24.

Burza MA, Motta BM, Mancina RM, Pingitore P, Pirazzi C, Lepore SM, Spagnuolo R, Doldo P, Russo C, Lazzaro V, Fischer J, Berg T, Aghemo A, Cheroni C, De Francesco R, Fargion S, Colombo M, Datz C, Stickel F, Valenti L, Romeo S (2016) DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection. Hepatology. 63:418–427. https://doi.org/10.1002/hep.28322 CrossRefPubMed

25.

Mohamed AA, Elsaid OM, Amer EA, Elosaily HH, Sleem MI, Gerges SS, Saleh MA, El Shimy A, El Abd YS (2017) Clinical significance of SNP (rs2596542) in histocompatibility complex class I-related gene a promoter region among hepatitis C virus related hepatocellular carcinoma cases. J Adv Res 8:343–349. https://doi.org/10.1016/j.jare.2017.03.004 CrossRefPubMedPubMedCentral

26.

Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. the METAVIR cooperative study group. Hepatology. 24:289–293. https://doi.org/10.1002/hep.510240201 CrossRefPubMed

27.

Alameri HF, Sanai FM, Al Dukhayil M, Azzam NA, Al-Swat KA, Hersi AS, Abdo AA (2007) Six minute walk test to assess functional capacity in chronic liver disease patients. World J Gastroenterol 13:3996–4001. https://doi.org/10.3748/wjg.v13.i29.3996 CrossRefPubMedPubMedCentral

28.

Bruix J, Sherman M (2011) American Association for the Study of Liver Diseases, management of hepatocellular carcinoma: an update. Hepatology. 53:1020–1022. https://doi.org/10.1002/hep.24199 CrossRefPubMedPubMedCentral

29.

Lahiri DK, Nurnberger JI (1991) A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 19:5444 http://www.ncbi.nlm.nih.gov/pubmed/1681511 CrossRef

30.

Rodriguez S, Gaunt TR, Day INM (2009) Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 169:505–514. https://doi.org/10.1093/aje/kwn359 CrossRefPubMedPubMedCentral

31.

Vescovo T, Refolo G, Vitagliano G, Fimia GM, Piacentini M (2016) Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma. Clin Microbiol Infect 22:853–861. https://doi.org/10.1016/j.cmi.2016.07.019 CrossRefPubMed

32.

Lo PHY, Urabe Y, Kumar V, Tanikawa C, Koike K, Kato N, Miki D, Chayama K, Kubo M, Nakamura Y, Matsuda K (2013) Identification of a functional variant in the MICA promoter which regulates MICA expression and increases HCV-related hepatocellular carcinoma risk. PLoS One 8:e61279. https://doi.org/10.1371/journal.pone.0061279 CrossRefPubMedPubMedCentral

33.

Michita RT, Chies JAB, Schramm S, Horn PA, Heinemann FM, Wunsch A, Viebahn R, Schenker P, Rebmann V (2018) A valine mismatch at position 129 of MICA is an independent predictor of Cytomegalovirus infection and acute kidney rejection in simultaneous pancreas⁻kidney transplantation recipients. Int J Mol Sci 19. https://doi.org/10.3390/ijms19092618

34.

Machiela MJ, Chanock SJ (2018) LDassoc: an online tool for interactively exploring genome-wide association study results and prioritizing variants for functional investigation. Bioinformatics. 34:887–889. https://doi.org/10.1093/bioinformatics/btx561 CrossRefPubMed

35.

Huang C-F, Huang C-Y, Yeh M-L, Wang S-C, Chen K-Y, Ko Y-M, Lin C-C, Tsai Y-S, Tsai P-C, Lin Z-Y, Chen S-C, Dai C-Y, Huang J-F, Chuang W-L, Yu M-L (2017) Genetics variants and serum levels of MHC class I chain-related a in predicting hepatocellular carcinoma development in chronic hepatitis C patients post antiviral treatment. EBioMedicine. 15:81–89. https://doi.org/10.1016/j.ebiom.2016.11.031 CrossRefPubMed

36.

Huang C-F, Huang C-I, Yeh M-L, Wang S-C, Chen K-Y, Ko Y-M, Lin C-C, Tsai Y-S, Tsai P-C, Lin Z-Y, Chen S-C, Dai C-Y, Huang J-F, Chuang W-L, Yu M-L (2017) Diversity of the association of serum levels and genetic variants of MHC class I polypeptide-related chain a with liver fibrosis in chronic hepatitis C. Oncotarget. 8:32618–32625. https://doi.org/10.18632/oncotarget.15941 CrossRefPubMedPubMedCentral

37.

Isernhagen A, Malzahn D, Bickeböller H, Dressel R (2016) Impact of the MICA-129Met/Val dimorphism on NKG2D-mediated biological functions and disease risks. Front Immunol 7:588. https://doi.org/10.3389/fimmu.2016.00588 CrossRefPubMedPubMedCentral

38.

Isernhagen A, Malzahn D, Viktorova E, Elsner L, Monecke S, von Bonin F, Kilisch M, Wermuth JM, Walther N, Balavarca Y, Stahl-Hennig C, Engelke M, Walter L, Bickeböller H, Kube D, Wulf G, Dressel R (2015) The MICA-129 dimorphism affects NKG2D signaling and outcome of hematopoietic stem cell transplantation. EMBO Mol Med 7:1480–1502. https://doi.org/10.15252/emmm.201505246 CrossRefPubMedPubMedCentral

39.

Vallian S, Rad MJ, Tavallaei M, Tavassoli M (2012) Correlation of major histocompatibility complex class I related a (MICA) polymorphism with the risk of developing breast cancer. Med Oncol 29:5–9. https://doi.org/10.1007/s12032-010-9776-9 CrossRefPubMed

40.

Chen D, Hammer J, Lindquist D, Idahl A, Gyllensten U (2014) A variant upstream of HLA-DRB1 and multiple variants in MICA influence susceptibility to cervical cancer in a Swedish population. Cancer Med 3:190–198. https://doi.org/10.1002/cam4.183 CrossRefPubMedPubMedCentral

41.

Tong HV, Toan NL, Song LH, Bock C-T, Kremsner PG, Velavan TP (2013) Hepatitis B virus-induced hepatocellular carcinoma: functional roles of MICA variants. J Viral Hepat 20:687–698. https://doi.org/10.1111/jvh.12089 CrossRefPubMed

42.

Chalupny NJ, Rein-Weston A, Dosch S, Cosman D (2006) Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem Biophys Res Commun 346:175–181. https://doi.org/10.1016/j.bbrc.2006.05.092 CrossRefPubMed

43.

Ashiru O, Bennett NJ, Boyle LH, Thomas M, Trowsdale J, Wills MR (2009) NKG2D ligand MICA is retained in the cis-Golgi apparatus by human cytomegalovirus protein UL142. J Virol 83:12345–12354. https://doi.org/10.1128/JVI.01175-09 CrossRefPubMedPubMedCentral

44.

Moenkemeyer M, Heiken H, Schmidt RE, Witte T (2009) Higher risk of cytomegalovirus reactivation in human immunodeficiency virus-1-infected patients homozygous for MICA5.1. Hum Immunol 70:175–178. https://doi.org/10.1016/j.humimm.2009.01.005 CrossRefPubMed

45.

Goto K, Kato N (2015) MICA SNPs and the NKG2D system in virus-induced HCC. J Gastroenterol 50:261–272. https://doi.org/10.1007/s00535-014-1000-9 CrossRefPubMed

46.

Goto K, Annan DA, Morita T, Li W, Muroyama R, Matsubara Y, Ito S, Nakagawa R, Tanoue Y, Jinushi M, Kato N (2016) Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study. Sci Rep 6:38407. https://doi.org/10.1038/srep38407 CrossRefPubMedPubMedCentral

47.

Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR (2009) Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia. 23:641–648. https://doi.org/10.1038/leu.2008.354 CrossRefPubMed

48.

Kuper H, Tzonou A, Kaklamani E, Hsieh C-C, Lagiou P, Adami H-O, Trichopoulos D, Stuver SO (2000) Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 85:498–502. https://doi.org/10.1002/(SICI)1097-0215(20000215)85:4<498::AID-IJC9>3.0.CO;2-F CrossRefPubMed

49.

Steinle A, Li P, Morris DL, Groh V, Lanier LL, Strong RK, Spies T (2001) Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics. 53:279–287. https://doi.org/10.1007/s002510100325 CrossRefPubMed

50.

Hayashi T, Imai K, Morishita Y, Hayashi I, Kusunoki Y, Nakachi K (2006) Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance. Cancer Res 66:563–570. https://doi.org/10.1158/0008-5472.CAN-05-2776 CrossRefPubMed

Title: Association between MICA rs2596542 Polymorphism with the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients
Authors: Camila Guerra Marangon
Jóice Teixeira de Bitencorte
Rafael Tomoya Michita
Vagner Ricardo Lunge
Deivid Cruz dos Santos
Mário Reis Álvares-da-Silva
Daniel Simon
Publication date: 01-07-2020
Publisher: Springer Netherlands
Keywords: Liver Cirrhosis
Hepatocellular Carcinoma
Hepatitis C
Hepatocellular Carcinoma
Published in: Pathology & Oncology Research / Issue 3/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-019-00738-6

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2020

Positive Correlative over-Expression between eIF4E and Snail in Nasopharyngeal Carcinoma Promotes its Metastasis and Resistance to Cisplatin

Correction to: Monoclonal Caveolin 1 Expression in the Differential Diagnosis of Malignant Pleural Mesothelioma and Pulmonary Adenocarcinoma: Is it Useful?

Diagnostic Accuracy of Immunohistochemistry for Mismatch Repair Proteins as Surrogate of Microsatellite Instability Molecular Testing in Endometrial Cancer

Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers

Simultaneous endocrine expression and loss of melanoma markers in malignant melanoma metastases, a retrospective analysis